Amgen Inc.

AMGN

US0311621009

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

298.6 USD

Average target price

316.4 USD

Spread / Average Target

+5.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMGEN INC.	+3.68%	160B
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 15/06/2024 am IST			5-day change	1st Jan Change
298.6 ^USD	+0.04%		-2.10%	+3.68%

14/06	Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	DJ
14/06	Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	MT

Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	15/06	DJ
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	15/06	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06	MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating	14/06	MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating	14/06	MT
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	13/06	MT
Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	10/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06	RE
Transcript : Amgen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM	06/06
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	05/06	MT
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD	05/06	DJ
Amgen's drug meets main goal in late-stage study for rare disease	05/06	RE
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)	05/06	CI
Amgen Inc. Appoints Dr. Mary E. Klotman as Director	04/06	CI
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	29/05	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	29/05	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	28/05	RE
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	22/05	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	22/05	MT
Transcript : Amgen Inc. - Special Call	21/05
HSBC Adjusts Price Target on Amgen to $356 From $322	20/05	MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results	20/05	MT
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	20/05	CI
US FDA approves Amgen drug for small cell lung cancer	17/05	RE
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer	17/05	CI